宫颈癌的 T 细胞免疫治疗：挑战与机遇。
T cell immunotherapy for cervical cancer: challenges and opportunities.
机构信息
School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出版信息
Front Immunol. 2023 Apr 26;14:1105265. doi: 10.3389/fimmu.2023.1105265. eCollection 2023.
Cancer cellular immunotherapy has made inspiring therapeutic effects in clinical practices, which brings new hope for the cure of cervical cancer. CD8+T cells are the effective cytotoxic effector cells against cancer in antitumor immunity, and T cells-based immunotherapy plays a crucial role in cellular immunotherapy. Tumor infiltrated Lymphocytes (TIL), the natural T cells, is approved for cervical cancer immunotherapy, and Engineered T cells therapy also has impressive progress. T cells with natural or engineered tumor antigen binding sites (CAR-T, TCR-T) are expanded , and re-infused back into the patients to eradicate tumor cells. This review summarizes the preclinical research and clinical applications of T cell-based immunotherapy for cervical cancer, and the challenges for cervical cancer immunotherapy.
癌症细胞免疫疗法在临床实践中取得了令人鼓舞的治疗效果，为宫颈癌的治愈带来了新的希望。CD8+T 细胞是抗肿瘤免疫中对抗癌症的有效细胞毒性效应细胞，基于 T 细胞的免疫疗法在细胞免疫疗法中起着至关重要的作用。肿瘤浸润淋巴细胞（TIL）是天然的 T 细胞，已被批准用于宫颈癌免疫治疗，工程 T 细胞疗法也取得了令人瞩目的进展。具有天然或工程肿瘤抗原结合位点的 T 细胞（CAR-T、TCR-T）被扩增，并重新输注回患者体内以消灭肿瘤细胞。本文综述了 T 细胞免疫疗法治疗宫颈癌的临床前研究和临床应用，以及宫颈癌免疫治疗面临的挑战。
Zotero 插件